Q-omics provides the consensus-scored MIR4675 profile across patient tissues and cancer cell-line models. MIR4675 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR4675 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, MIR4675 RNA expression shows 6,355 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, PRAD, and STAD as cancer lineages where MIR4675 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4675 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4675 survival associations across molecular data types. MIR4675 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4675 RNA expression–survival associations across cancer types. High MIR4675 expression shows unfavorable associations in UCEC, LUSC, SKCM and LUAD, but favorable associations in STAD and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR4675 RNA expression.
This table summarizes MIR4675 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4675. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4675 shows lower tumor expression in THCA and higher tumor expression in PRAD. The PRAD box plot shows higher MIR4675 RNA expression in tumor versus normal tissue (log2 FC = +0.130, t-test p = .046).
This table shows molecular features associated with MIR4675 in patient tissues and cancer cell lines. In patient samples, MIR4675 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
